Replies to post #594494 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Novocure’s device burns scalps, causes chronic headaches, is a bitch to carry around, and its farcical supposed long term survival is not real, it is an extrapolation from a very small quantity of a much larger group whose data was cutoff and buried two years after patients were randomized into the trial. The field array where Optune’s mechanism of action takes place has been found to inevitably allow tumor cell escape, meaning long term survival is the exception and possibly below standard of care. The Optune trial did not even bother to exclude all non-GBM Patients. Optune sucks.

[hoffmann6383]

Virtually every oncologist who treats GBM provides Optune as an option because unlike DCvax...

An option? Sure, at least here in the US. As far as uptake, we are looking sub 20% in the US and probably sub 10% if we look worldwide. Some countries don't even pay for it because they view it as a waste of money.

Washington State Health Authority on Optune:

"unproven efficacy"
"less cost-effective than comparators"
"...voted not to cover tumor treating fields for...newly diagnosed glioblastoma...recurrent...and for treatment of other cancers"$NVCR mkt cap = ~$7B$NWBO mkt cap = ~0.5B… pic.twitter.com/OW8lEANp8w

— Hoffmann (@hoffmann6383) April 26, 2023

[dstock07734]

Virtually every oncologist who treats GBM provides Optune as an option

Then tell us:
why does the increase in the number of patients using Optune become flat? Why did CEO dump almost all his position five months ago? If you are so confident in NVCR, why are you so scared of DCVax-L? If NVCR has confidence in its products, why did those doctors who have connections to NVCR jump out to belittle DCVax-L?

If a retailer still holds the share of a company whose CEO emptied all his position, is it a smart retailer?